A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: Differences between vaccine subtypes A multicontinental cohort study
Tekijät: Huespe Ivan A., Ferraris Augusto, Lalueza Antonio, Valdez Pascual R., Peroni Maria L., Cayetti Luis A., Mirofsky Matias A., Boietti Bruno, Gómez-Huelgas Ricardo, Casas-Rojo José M., Antón-Santos Juan M., Núñez-Cortés Jesús M., Lumbreras Carlos, Ramos-Rincón Jose-Manuel, Barrio Noelia G., Pedrera-Jiménez Miguel, Martin-Escalante María D., Ruiz Francisco R., Onieva-García María Á., Toso Carlos R., Risk Marcelo R., Klén Riku, Pollán Javier A., Gómez-Varela David
Kustantaja: Wiley
Julkaisuvuosi: 2023
Journal: Journal of Medical Virology
Tietokannassa oleva lehden nimi: Journal of medical virology
Lehden akronyymi: J Med Virol
Vuosikerta: 95
Numero: 5
ISSN: 0146-6615
eISSN: 1096-9071
DOI: https://doi.org/10.1002/jmv.28786
Verkko-osoite: https://doi.org/10.1002/jmv.28786
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/179760905
The aim of this study was to analyze whether the coronavirus disease 2019 (COVID-19) vaccine reduces mortality in patients with moderate or severe COVID-19 disease requiring oxygen therapy. A retrospective cohort study, with data from 148 hospitals in both Spain (111 hospitals) and Argentina (37 hospitals), was conducted. We evaluated hospitalized patients for COVID-19 older than 18 years with oxygen requirements. Vaccine protection against death was assessed through a multivariable logistic regression and propensity score matching. We also performed a subgroup analysis according to vaccine type. The adjusted model was used to determine the population attributable risk. Between January 2020 and May 2022, we evaluated 21,479 COVID-19 hospitalized patients with oxygen requirements. Of these, 338 (1.5%) patients received a single dose of the COVID-19 vaccine and 379 (1.8%) were fully vaccinated. In vaccinated patients, mortality was 20.9% (95% confidence interval [CI]: 17.9-24), compared to 19.5% (95% CI: 19-20) in unvaccinated patients, resulting in a crude odds ratio (OR) of 1.07 (95% CI: 0.89-1.29; p = 0.41). However, after considering the multiple comorbidities in the vaccinated group, the adjusted OR was 0.73 (95% CI: 0.56-0.95; p = 0.02) with a population attributable risk reduction of 4.3% (95% CI: 1-5). The higher risk reduction for mortality was with messenger RNA (mRNA) BNT162b2 (Pfizer) (OR 0.37; 95% CI: 0.23-0.59; p < 0.01), ChAdOx1 nCoV-19 (AstraZeneca) (OR 0.42; 95% CI: 0.20-0.86; p = 0.02), and mRNA-1273 (Moderna) (OR 0.68; 95% CI: 0.41-1.12; p = 0.13), and lower with Gam-COVID-Vac (Sputnik) (OR 0.93; 95% CI: 0.6-1.45; p = 0.76). COVID-19 vaccines significantly reduce the probability of death in patients suffering from a moderate or severe disease (oxygen therapy).
Ladattava julkaisu This is an electronic reprint of the original article. |  |
